IS2142B - Nýtt form S-ómeprasóls - Google Patents

Nýtt form S-ómeprasóls

Info

Publication number
IS2142B
IS2142B IS5272A IS5272A IS2142B IS 2142 B IS2142 B IS 2142B IS 5272 A IS5272 A IS 5272A IS 5272 A IS5272 A IS 5272A IS 2142 B IS2142 B IS 2142B
Authority
IS
Iceland
Prior art keywords
omeprazole
new form
new
Prior art date
Application number
IS5272A
Other languages
English (en)
Icelandic (is)
Other versions
IS5272A (is
Inventor
Cotton Hanna
Kronstr÷M Anders
Mattson Anders
M÷Ller Eva
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2142(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS5272A publication Critical patent/IS5272A/is
Publication of IS2142B publication Critical patent/IS2142B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
IS5272A 1997-05-30 1999-11-25 Nýtt form S-ómeprasóls IS2142B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening
PCT/SE1998/000974 WO1998054171A1 (en) 1997-05-30 1998-05-25 Novel form of s-omeprazole

Publications (2)

Publication Number Publication Date
IS5272A IS5272A (is) 1999-11-25
IS2142B true IS2142B (is) 2006-09-15

Family

ID=20407186

Family Applications (2)

Application Number Title Priority Date Filing Date
IS5272A IS2142B (is) 1997-05-30 1999-11-25 Nýtt form S-ómeprasóls
IS8368A IS2774B (is) 1997-05-30 2006-03-22 Ný aðferð til að framleiða tríhýdrat magnesíumsalt S-ómeprasóls

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8368A IS2774B (is) 1997-05-30 2006-03-22 Ný aðferð til að framleiða tríhýdrat magnesíumsalt S-ómeprasóls

Country Status (43)

Country Link
US (6) US6369085B1 (instruction)
EP (2) EP1273581B1 (instruction)
JP (2) JP4002303B2 (instruction)
KR (2) KR100540720B1 (instruction)
CN (1) CN1161351C (instruction)
AR (2) AR012717A1 (instruction)
AT (2) ATE291574T1 (instruction)
AU (1) AU722839B2 (instruction)
BR (1) BR9809509A (instruction)
CA (2) CA2521391C (instruction)
CY (1) CY2012029I1 (instruction)
CZ (1) CZ297585B6 (instruction)
DE (3) DE69814069T3 (instruction)
DK (2) DK0984957T3 (instruction)
DZ (1) DZ2495A1 (instruction)
EE (1) EE03875B1 (instruction)
EG (1) EG24291A (instruction)
ES (2) ES2236407T3 (instruction)
HR (1) HRP980263B1 (instruction)
HU (1) HU225987B1 (instruction)
ID (1) ID29306A (instruction)
IL (1) IL132947A0 (instruction)
IS (2) IS2142B (instruction)
LU (2) LU91871I2 (instruction)
MA (1) MA26500A1 (instruction)
ME (3) MEP18008A (instruction)
MY (2) MY127793A (instruction)
NO (3) NO317518B1 (instruction)
NZ (1) NZ500991A (instruction)
PL (1) PL193546B1 (instruction)
PT (2) PT1273581E (instruction)
RS (2) RS50005B (instruction)
RU (1) RU2184115C2 (instruction)
SA (2) SA98190280B1 (instruction)
SE (1) SE510650C2 (instruction)
SI (2) SI0984957T1 (instruction)
SK (2) SK285137B6 (instruction)
TN (1) TNSN98074A1 (instruction)
TR (1) TR199902934T2 (instruction)
TW (1) TW538040B (instruction)
UA (1) UA60334C2 (instruction)
WO (1) WO1998054171A1 (instruction)
ZA (1) ZA984179B (instruction)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
DE69737413T2 (de) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville Bakterioferritin aus helicobacter pylori
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60314105T2 (de) 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
AU2003247729B2 (en) * 2002-06-27 2009-10-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US7612098B2 (en) * 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
CN1728997A (zh) * 2002-10-22 2006-02-01 兰贝克赛实验室有限公司 (es)奥美拉唑的无定形盐
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
US20060094762A1 (en) * 2003-01-07 2006-05-04 Yatendra Kumar Magnesium salt of imidazole derivative
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
EP1633736A1 (en) 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
PL1651217T3 (pl) * 2003-07-23 2008-07-31 Nycomed Gmbh Sole alkaiczne inhibitorów pompy protonowej
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
BRPI0507837A (pt) * 2004-02-18 2007-07-10 Allergan Inc métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
CN103121992A (zh) * 2004-06-24 2013-05-29 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
EP1885711A1 (en) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
WO2006134605A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
US7576219B2 (en) * 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
JP5017274B2 (ja) * 2005-10-26 2012-09-05 ハンミ・サイエンス・カンパニー・リミテッド Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
EP2040710A2 (en) * 2006-06-21 2009-04-01 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
KR101522865B1 (ko) * 2007-02-21 2015-05-26 시플라 리미티드 에소메프라졸 마그네슘 2수화물의 형태 a의 제조방법
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2008149204A1 (en) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN104069088A (zh) 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr PREPARATION OF MAGNESIUM OF ESOMEPRAZOLE AND ITS HYDRATES
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010150276A2 (en) * 2009-06-02 2010-12-29 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
MX2012000057A (es) * 2009-06-25 2012-06-01 Pozen Inc Metodo para tratar a un paciente con necesidad de terapia de aspirina.
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
EP2510089B1 (en) 2009-12-08 2015-10-21 Codexis, Inc. Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102936238B (zh) * 2011-11-25 2015-02-18 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) * 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
EP3842575A4 (en) * 2018-08-21 2022-06-01 Towa Pharmaceutical Co., Ltd. SPECIFIC SHAPED CRYSTAL OF A COMPOUND AND METHOD OF PRODUCTION THEREOF
WO2020040438A1 (ko) 2018-08-23 2020-02-27 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
HUT75775A (en) 1994-07-08 1997-05-28 Astra Ab Medicament with multiple unit tablated dosage form containing omeprazole
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US5948913A (en) 1994-11-14 1999-09-07 Daiichi Pharmaceutical Co., Ltd. Hydrate for drug use
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
DK0984957T3 (da) 2003-06-30
CA2521391C (en) 2009-09-29
US20120252847A1 (en) 2012-10-04
US20020198239A1 (en) 2002-12-26
RU2184115C2 (ru) 2002-06-27
HU0001849D0 (instruction) 2002-05-29
DE69814069T3 (de) 2014-03-27
HU225987B1 (en) 2008-02-28
CA2290963C (en) 2006-03-28
CA2290963A1 (en) 1998-12-03
BR9809509A (pt) 2000-06-20
ATE239011T1 (de) 2003-05-15
CN1258295A (zh) 2000-06-28
HRP980263B1 (en) 2002-02-28
EE9900550A (et) 2000-06-15
RS50067B (sr) 2009-01-22
DE69829511D1 (de) 2005-04-28
HK1051681A1 (en) 2003-08-15
PL193546B1 (pl) 2007-02-28
SE9702065L (sv) 1998-12-01
IS5272A (is) 1999-11-25
SI1273581T1 (instruction) 2005-08-31
SK285137B6 (sk) 2006-07-07
ZA984179B (en) 1998-11-30
CY2012029I2 (el) 2015-08-05
CA2521391A1 (en) 1998-12-03
AU7793598A (en) 1998-12-30
PL337180A1 (en) 2000-08-14
MA26500A1 (fr) 2004-12-20
EE03875B1 (et) 2002-10-15
US20050075369A1 (en) 2005-04-07
JP2002501529A (ja) 2002-01-15
US6677455B2 (en) 2004-01-13
IS2774B (is) 2012-03-15
EP1273581B1 (en) 2005-03-23
TNSN98074A1 (fr) 2005-03-15
DE69814069T2 (de) 2004-04-01
WO1998054171A1 (en) 1998-12-03
NO995852D0 (no) 1999-11-29
US7745466B2 (en) 2010-06-29
HK1025962A1 (en) 2000-12-01
NO317518B1 (no) 2004-11-08
SK162599A3 (en) 2000-06-12
US8466175B2 (en) 2013-06-18
US8076361B2 (en) 2011-12-13
DE69829511T2 (de) 2006-02-16
JP2007161734A (ja) 2007-06-28
EG24291A (en) 2009-01-08
YU60999A (sh) 2002-03-18
MY127793A (en) 2006-12-29
LU92017I2 (fr) 2012-08-06
DE122012000017I1 (de) 2012-08-16
ID29306A (id) 2001-08-16
EP0984957B3 (en) 2013-09-18
HUP0001849A3 (en) 2003-02-28
AR012717A1 (es) 2000-11-08
JP4002303B2 (ja) 2007-10-31
DZ2495A1 (fr) 2003-01-25
ES2236407T3 (es) 2005-07-16
MEP24908A (en) 2010-10-10
SA05260296B1 (ar) 2008-04-16
SE510650C2 (sv) 1999-06-14
TW538040B (en) 2003-06-21
ME00198B (me) 2011-02-10
PT1273581E (pt) 2005-06-30
SE9702065D0 (sv) 1997-05-30
US20080255363A1 (en) 2008-10-16
EP1273581A1 (en) 2003-01-08
DK1273581T3 (da) 2005-06-06
US20110130570A1 (en) 2011-06-02
MY120745A (en) 2005-11-30
RS50005B (sr) 2008-09-29
ATE291574T1 (de) 2005-04-15
TR199902934T2 (xx) 2000-04-21
SK284837B6 (sk) 2005-12-01
RS20070459A (en) 2008-06-05
HUP0001849A2 (hu) 2002-05-29
KR20010013126A (ko) 2001-02-26
CN1161351C (zh) 2004-08-11
ES2195345T3 (es) 2003-12-01
SI0984957T1 (en) 2003-10-31
NO995852L (no) 2000-01-31
US6369085B1 (en) 2002-04-09
CZ297585B6 (cs) 2007-01-10
IS8368A (is) 2006-03-22
IL132947A0 (en) 2001-03-19
KR20050042827A (ko) 2005-05-10
UA60334C2 (uk) 2003-10-15
DE69814069D1 (de) 2003-06-05
AR059589A2 (es) 2008-04-16
KR100540720B1 (ko) 2006-01-12
US7411070B2 (en) 2008-08-12
NO2012011I1 (no) 2012-06-18
EP0984957A1 (en) 2000-03-15
HRP980263A2 (en) 1999-02-28
AU722839B2 (en) 2000-08-10
NZ500991A (en) 2001-05-25
LU91871I2 (fr) 2011-11-21
EP0984957B1 (en) 2003-05-02
CY2012029I1 (el) 2015-08-05
MEP18008A (en) 2010-10-10
KR100527804B1 (ko) 2005-11-15
PT984957E (pt) 2003-07-31
SA98190280B1 (ar) 2006-07-04
ES2195345T7 (es) 2014-01-15
NO2011010I1 (no) 2011-06-20
WO1998054171A8 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
CY2012029I1 (el) Νεα μορφη της s-ομεπραζολης
EE9900540A (et) Omeprasooli ravimvorm
ID27092A (id) Pembuatan ftalat anhidrida
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
DK0994890T3 (da) Benzimidazolderivater
ID24481A (id) Gastrokinetik monosiklik benzamida dari derivat-3-atau-tersubstitusi 4-(aminometil)-piperidin
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
ID24458A (id) Modifikasi rheologi in-sito poliolefin
PT1036083E (pt) Novos 9a-azalidos
EE04154B1 (et) Omeprasooli valmistamise meetod
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
PT964867E (pt) Antagonistas da taquicinima
DK0983266T3 (da) Hidtil ukendte tetrahydrosioquinolinthiophencarboximidamider
ID30381A (id) Penggunaan arilalkanoilpiridazina
FI974544A0 (fi) Anordning i en med manoeverplats foersedd lastkran
FI974235A0 (fi) Ny bestaemningsmetod
FI971324A0 (fi) Maet- och reglerfoerfarande och -arrangemang foer konsistens
FI972138A0 (fi) Returtraog i bestrykningsanordning
KR970021293U (ko) 특허 출원서 행정 양식
UA2072S (uk) Набір блюд
UA1976S (uk) Марля
BR9704807A (pt) Super tijolo do tocantins
FI3228U1 (fi) Savustusuuni
FI971766A0 (fi) Savustuslaatikko
FI971071A0 (fi) Minneselement i samband med medicinfoerpackning